J Korean Med Sci.  2010 Oct;25(10):1431-1437. 10.3346/jkms.2010.25.10.1431.

Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus

• Lee YH
• Choe JY
• Park SH
• Park YW
• Lee SS
• Kang YM
• Nam EJ
• Park W
• Kwon SR
• Bae SC
• Kim YJ
• Suh CH
• Kim HA
• Hur NW
• Lee J

• KMID: 2157845
• DOI: http://doi.org/10.3346/jkms.2010.25.10.1431

Abstract

We performed a multicenter cross-sectional study of 134 sexually active systemic lupus erythematosus (SLE) patients to investigate the prevalence of and risk factors for high risk human papilloma virus (HPV) infection and cervical cytological abnormalities among Korean women with SLE. In this multicenter cross-sectional study, HPV testing and routine cervical cytologic examination was performed. HPV was typed using a hybrid method or the polymerase chain reaction. Data on 4,595 healthy women were used for comparison. SLE patients had greater prevalence of high-risk HPV infection (24.6% vs. 7.9%, P<0.001, odds ratio 3.8, 95% confidence interval 2.5-5.7) and of abnormal cervical cytology (16.4 vs. 2.8%, P<0.001, OR 4.4, 95% CI 2.5-7.8) compared with controls. SLE itself was identified as independent risk factors for high risk HPV infection among Korean women (OR 3.8, 95% CI 2.5-5.7) along with > or =2 sexual partners (OR 8.5, 95% CI 1.2-61.6), and Pap smear abnormalities (OR 97.3, 95% CI 6.5-1,456.7). High-risk HPV infection and cervical cytological abnormalities were more common among Korean women with SLE than controls. SLE itself may be a risk factor for HPV infection among Korean women, suggesting the importance of close monitoring of HPV infections and abnormal Pap smears in SLE patients.

Keyword

Systemic Lupus Erythematosus, Human Papilloma Virus; Cervical Cytological Abnormalities

MeSH Terms

Adult
Cervix Uteri/*pathology
Cross-Sectional Studies
Female
Humans
Lupus Erythematosus, Systemic/*complications/pathology
Middle Aged
Odds Ratio
Papillomavirus Infections/complications/*epidemiology
Prevalence
Republic of Korea
Risk Factors
Vaginal Smears
Women

Reference

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189:12–19.

2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003. 88:63–73.

3. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int. 2004. 17:366–369.

4. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol. 2000. 96:403–409.

5. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997. 337:1343–1349.

6. Stricker H, Colucci G, Godio M, Mossi G, Mombelli G. The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects: evidence of reduced thrombin generation. J Thromb Haemost. 2003. 1:380–381.

7. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005. 80:2 Suppl. S254–S264.

8. Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, Cason J. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007. 57:619–625.

9. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004. 50:3619–3625.

10. Rus V ME, Hochberg MC. Wallace DJ, Hahn BH. The epidemiology of systemic lupus erythematosus. Dubois' lupus erythematosus. 2007. Philadelphia: Lippincott Williams & Wilkins;65–83.

11. Oh JK, Franceschi S, Kim BK, Kim JY, Ju YH, Hong EK, Cahang YC, Rha SH, Kim HH, Kim JH, Kim CY, Shin HR. Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea. Eur J Cancer Prev. 2009. 18:56–61.

12. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, Park JS. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol. 2003. 89:210–217.

13. Berthier S, Mougin C, Vercherin P, Desmurs H, Gil H, de Wazieres B, Dupond JL. Does a particular risk associated with papillomavirus infections exist in women with lupus? Rev Med Interne. 1999. 20:128–132.

14. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Forhat S, Broering J, Darragh T, Palefsky J. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001. 285:2995–3002.

15. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensece M, Suhr CJ, Weinstock H, Helmerhorst TJ. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008. 148:493–500.

16. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol. 2005. 58:1096–1100.

17. Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum Pathol. 1986. 17:254–263.

18. Pisetsky DS. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev. 2008. 8:69–72.

19. Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R, Bermudez-Morales V, Peralta-Zaragoza O, Hernandez-Pando R, Moreno J, Gariglio P, Madrid-Marina V. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006. 19:481–491.

20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998. 338:423–428.

21. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum. 1981. 24:648–650.

22. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus. 2000. 9:542–544.

23. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004. 31:1763–1767.

24. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003. 31:20–28.

25. World Health Organization.int [website on the internet]. c2008. accessed on Sep 5, 2008. World Health Organization;[updated 2007]. Available from http://www.who.int/hpvcentre/en.

26. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005. 52:1481–1490.

27. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004. 103:304–309.

28. Cancer.go.kr [website on the internet]. C2008. accessed on Aug 28, 2008. National Cancer Information Center;Available from http://www.cancer.go.kr.

29. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 yr of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006. 367:1247–1255.

30. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006. 24:5571–5583.